

NZX Announcement

Market Release

28 April 2020

Truscreen announces the opening of a \$2.0 million Share Purchase Plan

Truscreen Limited (NZX:TRU) is pleased to announce the opening of a \$2.0 million share purchase plan ("SPP") today.

Eligible New Zealand shareholders and Wholesale investors in Australia will receive their personalised application forms to apply for up to a maximum of NZ\$50,000 of new shares per shareholder, at \$0.05 per share. The issue price comprises a 51.22% discount on the five day volume weighted average price of TRU shares traded on the NZX during the last five trading days prior to the date of this announcement.

The SPP Offer Document will be sent to eligible shareholders today and can be found online at www.truscreenshareoffer.co.nz.

The funds raised from the SPP will be applied towards:

- Growing and increasing TruScreen's presence in the Chinese market;
- Developing other global markets with a focus on Vietnam, Russia and India; and
- Providing additional working capital.

The key dates for the SPP offer are as follows:

Key Dates	
Record Date	Friday, 24 April 2020
SPP Offer Opens	Tuesday, 28 April 2020
SPP Offer Closes	Thursday, 14 May 2020
Allotment of Shares	Thursday, 21 May 2020
Commencement of trading of shares on NZX	Thursday, 21 May 2020

A copy of the Corporate Action Notice, the Cleansing Notice, the Offer Document and Application Form, and the Investor Presentation accompany this announcement.

Ends

For investor relations queries please contact:

Guy Robertson
Chief Financial Officer
Tel: +61 407 983 270

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.



TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen's target market is low- and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDA-approved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: <http://truscreen.com/truscreen-the-company/truscreen-ultra-video/>